Allarity Therapeutics expands in-house lab to add proteomics, cell line research
Bitget2026/09/28 12:04- Allarity Therapeutics expanded its in-house medical laboratory to add proteomics and cell line research capabilities.
- Build-out targets deeper mechanism-of-action work on lead asset stenoparib, a dual PARP and WNT pathway inhibitor in Phase 2.
- New services broaden the lab’s external offering, adding to existing transcriptomics research and CLIA clinical testing.
- nCounter Pro platform now supports proteomics via the Human Tumor Signaling Protein Panel, measuring about 300 protein targets.
- Expansion is not expected to change cash runway, with management pointing to cost efficiencies from bringing more research in-house.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The new Roadster is about to debut: Is "Tesla can fly" just hype or reality?
BUZZ - Super Micro appoints Mark Long as Chief Financial Officer; shares fall
The US stock market opened mixed, with the Nasdaq down 331 points.
"Super bull" Yardeni lowers S&P year-end target: Earnings are not the problem, valuation is
Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.
Crypto prices
More
